Fresh analysis reveals that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise programs.
Research printed in a leading medical journal demonstrates that while overweight individuals often shed about a fifth of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying these treatments need to be informed of the potential of quick rebound weight gain when the medication concludes," warns expert Dr. Susan Jebb.
That rate of regain implies a reversion to original weight in about one and a half years.
Analyzing Approaches
The research, which looked at 37 of studies involving thousands of participants, compared the outcomes of the injectable medications with older methods.
Researchers note that individuals who shed pounds through dieting generally see a slower weight regain—around 100 grams monthly—once they finish.
Explaining the Quick Rebound
Experts propose the mechanism of the drugs is key to understanding the heightened regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production could lead to the body to produce less of its endogenous hormone, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement results in hunger is unsuppressed, making overeating a significant risk."
An Ongoing Condition?
The NHS recommend the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals argue that, due to the high risk of relapse, the treatment is often life-long.
This view is supported by pharmaceutical companies, who state that the findings "highlight the long-term nature of excess weight," similar to managing conditions like high blood pressure.
User Testimonies
Users who have come off the medication describe a intense return of appetite.
"I experienced a switch that goes on and you're instantly extremely hungry," recalled one woman.
This difficulty is compounded if users have not adopted lasting dietary or behavioural changes during treatment.
Significant Use
Survey data show that a significant number of people in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Use is more common among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic fix and maintained weight loss hinges on combined behavioural management.
